What is late-stage tuberculosis (TB)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is Latent Tuberculosis Infection (LTBI)?

Latent tuberculosis infection (LTBI) is characterized by the presence of immune responses to previously acquired Mycobacterium tuberculosis infection without any clinical evidence of active tuberculosis disease. 1

Key Defining Features

  • No symptoms or signs of active TB disease – Patients with LTBI are completely asymptomatic and have no clinical manifestations of tuberculosis 1

  • Not infectious – Individuals with LTBI cannot transmit the infection to others, as the bacteria are dormant and not actively replicating 1

  • Positive immunologic testing – LTBI is detected through positive tuberculin skin test (TST) or interferon-gamma release assay (IGRA), indicating immune response to M. tuberculosis 1

  • Normal chest radiograph – There is no radiographic evidence of active pulmonary tuberculosis, though old calcifications or pleural thickening may suggest prior exposure 1

Epidemiology and Risk of Progression

  • Approximately one-third of the world's population is estimated to be infected with Mycobacterium tuberculosis 1

  • Lifetime reactivation risk is 5-15% for persons with documented LTBI, with the majority developing active TB disease within the first 5 years after initial infection 1

  • Risk varies significantly by host factors – HIV infection, immunosuppressive therapy (especially anti-TNF agents), diabetes, silicosis, chronic renal failure, and malnutrition substantially increase the risk of progression from LTBI to active disease 1

Clinical Significance

The reactivation of LTBI to active TB can be prevented by treatment, with currently available regimens demonstrating 60-90% efficacy, with protection lasting up to 19 years 1. This makes identification and treatment of high-risk individuals a critical component of TB elimination strategies, particularly in low TB incidence countries 1.

The distinction between LTBI and active TB disease is crucial because treatment regimens, duration, public health implications, and monitoring requirements differ substantially between the two conditions 1, 2, 3.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

The Treatment of Tuberculosis.

Clinical pharmacology and therapeutics, 2021

Research

Tuberculosis: Common Questions and Answers.

American family physician, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.